ALNY Alnylam Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ALNY
Price (delayed)
$429.93
Market cap
$56.35B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.47
Enterprise value
$58.39B
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is
Highlights
The equity has soared by 117% from the previous quarter
The company's revenue rose by 5% YoY and by 4.8% QoQ
The company's net income fell by 18% QoQ
ALNY's EPS is down by 18% since the previous quarter
Key stats
What are the main financial stats of ALNY
Market
Valuations
Earnings
Shares outstanding
131.08M
Market cap
$56.35B
Enterprise value
$58.39B
Price to earnings (P/E)
N/A
Price to book (P/B)
223.7
Price to sales (P/S)
22.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.72
Revenue
$2.46B
Gross profit
$2.06B
Operating income
-$180.19M
Net income
-$319.09M
EBIT
-$227.34M
EBITDA
-$192.5M
Free cash flow
-$52.09M
Per share
Balance sheet
Liquidity
EPS
-$2.47
EPS diluted
-$2.47
Free cash flow per share
-$0.4
Book value per share
$1.92
Revenue per share
$18.85
TBVPS
$34.95
Total assets
$4.57B
Total liabilities
$4.32B
Debt
$3.15B
Equity
$250.59M
Working capital
$2.34B
Debt to equity
12.56
Current ratio
2.8
Quick ratio
2.63
Net debt/EBITDA
-10.56
Margins
Efficiency
Dividend
EBITDA margin
-7.8%
Gross margin
83.6%
Net margin
-13%
Operating margin
-7.3%
Return on assets
-7.4%
Return on equity
-274.2%
Return on invested capital
-4.5%
Return on capital employed
-7%
Return on sales
-9.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALNY stock price
How has the Alnylam Pharmaceuticals stock price performed over time
Intraday
-1.17%
1 week
2.63%
1 month
36.51%
1 year
59.13%
YTD
82.71%
QTD
31.84%
Financial performance
How have Alnylam Pharmaceuticals's revenue and profit performed over time
Revenue
$2.46B
Gross profit
$2.06B
Operating income
-$180.19M
Net income
-$319.09M
Gross margin
83.6%
Net margin
-13%
Alnylam Pharmaceuticals's operating income has shrunk by 56% QoQ
The company's operating margin fell by 49% QoQ
The company's net income fell by 18% QoQ
The net margin has contracted by 13% from the previous quarter
Price vs fundamentals
How does ALNY's price correlate with its fundamentals
Growth
What is Alnylam Pharmaceuticals's growth rate over time
Valuation
What is Alnylam Pharmaceuticals stock price valuation
P/E
N/A
P/B
223.7
P/S
22.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.72
ALNY's EPS is down by 18% since the previous quarter
The equity has soared by 117% from the previous quarter
ALNY's price to book (P/B) is 56% less than its last 4 quarters average of 504.1
ALNY's price to sales (P/S) is 46% higher than its last 4 quarters average of 15.6 and 6% higher than its 5-year quarterly average of 21.6
The company's revenue rose by 5% YoY and by 4.8% QoQ
Efficiency
How efficient is Alnylam Pharmaceuticals business performance
The ROE has grown by 46% from the previous quarter
The return on assets has declined by 14% since the previous quarter
ALNY's return on invested capital is down by 7% since the previous quarter
ALNY's return on sales is down by 3.4% since the previous quarter
Dividends
What is ALNY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALNY.
Financial health
How did Alnylam Pharmaceuticals financials performed over time
The total assets is 6% more than the total liabilities
The total assets has increased by 14% YoY and by 8% from the previous quarter
The company's total liabilities rose by 8% YoY and by 5% QoQ
The equity has soared by 117% from the previous quarter
Alnylam Pharmaceuticals's debt to equity has soared by 101% YoY but it has plunged by 54% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.